http://www.ipo.uc.edu/index.cfm?fuseaction=patents.list This is the rss feed for patents issued to the University of Cincinnati. Please note that some of these are already committed to a licensee, please feel free to contact someone in the office by calling 513-558-6293 Tue, 13 Oct 2009 00:00:00 GMT en-us http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,601,269 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,601,269 Tue, 13 Oct 2009 00:00:00 GMT A novel filter-less separation technique for separating suspended particles from a solution is disclosed. More specifically, an on-chip bioparticle separator is disclosed, which relies on the differential force exerted by application of a series of high magnitude, short duration pressure pulses on bioparticles in suspension within microchannels, resulting in separation of suspended bioparticles. The filter-less separation technique is inherently suited to .mu.TAS (Micro Total Analysis System) since it exploits uniquely microscale phenomena to achieve separation. The on-chip bioparticle separator can be easily integrated with a disposable biochip, can be fabricated using low-cost, rapid manufacturing techniques, and can provide high performance for separation of bioparticles without the use of specialized or expensive equipment. Embodiments of the present invention address a significant challenge in the development of disposable microfluidic biochips, specifically, providing a reliable solution for separating bioparticles in a microfluidic system that may be immediately applied for a variety of microfluidic biochip applications. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,598,052 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,598,052 Tue, 06 Oct 2009 00:00:00 GMT The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,572,603 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,572,603 Tue, 11 Aug 2009 00:00:00 GMT The present invention includes polymorphisms in nucleic acids encoding the alpha-2B, alpha-2A, and alpha-2C adrenergic receptor and expressed alpha-2B, alpha-2A and alpha-2C adrenergic receptor molecule. The invention also pertains to methods and molecules for detecting such polymorphisms. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment of diseases such as cardiovascular and central nervous system disease. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,539,580 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,539,580 Tue, 26 May 2009 00:00:00 GMT A computer implemented method for examining data from a chemical analyzer for artifactual results is provided. A set of rules are established to identify artifactual results based upon experience with the analyzer. Each rule can be associated with a sample collection or testing problem which potentially caused the artifactual result. Using these rules, output data from the analyzer can be tested to see if any of the rules are satisfied. If a rule is satisfied, then an artifactual result can be indicated, as well as the potential cause of the artifactual result. An output file can be created which indicates the artifactual data samples and the potential artifactual causes. The rules file and output file may be provided in a user-friendly format, such as in a spreadsheet or database application format. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,524,464 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,524,464 Tue, 28 Apr 2009 00:00:00 GMT Disclosed herein is a fully-integrated, disposable biochip for point-of-care testing of clinically relevant parameters. Specifically, in accordance with an embodiment of the present invention, the biochip is designed for POCT (point-of-care-testing) of an array of metabolic parameters including partial pressure of oxygen, Glucose, and Lactate concentration from venous blood samples. The biochip is fabricated on a low-cost plastic substrate using mass manufacturing compatible fabrication processes. Furthermore, the biochip contains a fully-integrated metallic micro-needle for blood sampling. The biochip also uses smart passive microfluidics in conjunction with low-power functional on-chip pressure generators for microfluidic sequencing. The design, configuration, assembly and operation of the biochip are ideally suited for a disposable biochip specifically targeted towards POCT applications. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,482,421 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,482,421 Tue, 27 Jan 2009 00:00:00 GMT A silane film that can be used in a wide range of environments, on metals of engineering interest, as a standalone process or as a primer for a top-coating by common paint systems. The film generally comprises: a) at least one bis-silane; b) a water soluble or dispersible polymer; c) nanoparticles; and, d) a water soluble solvent. It is also within the scope of the present invention to include a leachable inhibitor into the silane film. In sum, the present invention teaches a silane composition that may be applied by dipping, wiping, spraying, brushing, or other conventional techniques, whereby the film composition provides a metal treatment that is water soluble and may provide the availability of the coating to "heal" by utilizing a leachable inhibitor whenever damage occurs from scrapes or scratches. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,476,326 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,476,326 Tue, 13 Jan 2009 00:00:00 GMT A novel filter-less separation technique for separating suspended particles from a solution is disclosed. More specifically, an on-chip bioparticle separator is disclosed, which relies on the differential force exerted by application of a series of high magnitude, short duration pressure pulses on bioparticles in suspension within microchannels, resulting in separation of suspended bioparticles. The filter-less separation technique is inherently suited to .mu.TAS (Micro Total Analysis System) since it exploits uniquely microscale phenomena to achieve separation. The on-chip bioparticle separator can be easily integrated with a disposable biochip, can be fabricated using low-cost, rapid manufacturing techniques, and can provide high performance for separation of bioparticles without the use of specialized or expensive equipment. Embodiments of the present invention address a significant challenge in the development of disposable microfluidic biochips, specifically, providing a reliable solution for separating bioparticles in a microfluidic system that may be immediately applied for a variety of microfluidic biochip applications. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,465,710 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,465,710 Tue, 16 Dec 2008 00:00:00 GMT This invention relates generally to dipeptides and tripeptides and to methods for pharmaceutical treatment of mammals using analogs of such dipeptides and tripeptides. More specifically, the invention relates to tripeptides and their analogs, to pharmaceutical compositions containing such dipeptides and tripeptides and to methods of treatment of mammals using such dipeptides and tripeptides. In addition, the invention relates to methods of treatment of mammals using such dipeptides and tripeptides for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,452,720 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,452,720 Tue, 18 Nov 2008 00:00:00 GMT An apparatus and method of using the apparatus to prepare a biocompatible biodegradable matrix capable of supporting cells to form an implantable or engraftable surgical device. A matrix-forming fluid is contained within a chamber defined by top and bottom surfaces of a thermally conductive material and spacers defining the thickness of the matrix. The chamber is then cooled to freeze the solution at a controlled rate, resulting in a matrix with a desired and uniform thickness having symmetric and uniform reticulations. The apparatus and method reproducibly forms such a matrix, which may be populated with cells for transplantation and engraftment into a wound. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,449,292 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,449,292 Tue, 11 Nov 2008 00:00:00 GMT Methods and compositions for the detection, diagnosis, and prevention of cardiac conditions are provided. Polymorphisms of .beta..sub.1-adrenergic receptor are provided. The Gly389 .beta..sub.1-adrenergic receptor variants are not as responsive to treatment .beta. blockers such as carvedilol, metoprolol or bisoprol. Thus, genotyping .beta..sub.1-adrenergic receptor polymorphisms is useful for predicting relative responsiveness to treatment with beta blockers. The Gly389 polymorphism also may be used, alone or in conjunction with other adrenergic receptor polymorphisms, to predict relative risk of developing cardiovascular diseases such as heart failure or to predict relative survival rate in patients with heart failure or other cardiovascular diseases. Also provided are transgenic mice and transgenic cells expressing the .beta..sub.1-adrenergic receptor polymorphisms, and their use in identifying therapeutic agents. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,450,983 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,450,983 Tue, 11 Nov 2008 00:00:00 GMT Brain Magnetic Resonance Imaging (MRI), Computerized Tomotography (CT), or other diagnostic modalities may employ a three-step procedure during initial ("scout") cranial pre-scans that corrects for patient positioning (i.e., roll, yaw and pitch) to reduce inter- and intra-patient variation, thereby enhancing the diagnostic and comparative value of subsequent detail scans even across different diagnostic platforms. In MRI, for instance, locating the saggital sinus (SS) and optimizing a line to bisect the brain through this SS may be automated to correct for roll and yaw. By then identifying the contour of the corpus callosum in a lateral saggital scout scan, the Talairach anterior commissure (AC)--posterior commissure (PC) reference line may be found for correcting pitch. Prescription of detailed scans are improved, especially when the three-step correction is repeated periodically identifying the need to repeat a detailed scan or to adjust the coordinates of a subsequent scan. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,430,355 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,430,355 Tue, 30 Sep 2008 00:00:00 GMT A signage device comprising one or more light sources, a waveguide or arrangement of waveguides and photoluminescent features coupled thereto. In one embodiment, a waveguide is adapted to receive light of a first wavelength and the photoluminescent features are adapted to emit light of a second wavelength in response to receiving light of the first wavelength. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,380,224 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,380,224 Tue, 27 May 2008 00:00:00 GMT A computerized method and system for solving non-linear Boolean equations is disclosed comprising at least partially solving a Boolean function; developing at least one inference regarding said Boolean function and saving said inference to a state machine; and accessing said inference from said state machine to develop at least one heuristic for determining whether said Boolean function is satisfiable. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,378,385 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,378,385 Tue, 27 May 2008 00:00:00 GMT GLP-1 and GLP-1 receptor antagonists have been found to have a sedative or anxiolytic effect on the mammalian central nervous system. Conversely, GLP-1 and GLP-1 receptor agonists increase nervous system activity and the stress response. The invention relates, in one aspect, to the use of GLP-1 agonists and antagonists to modulate the stress response in a mammal. In an aspect GLP-1 and GLP-1 receptor antagonists are used to treat stress-related disorders. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,361,191 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,361,191 Tue, 22 Apr 2008 00:00:00 GMT An actuation system for assisting the operation of the natural heart comprises a framework for interfacing with a natural heart, through the wall of the heart, which includes an internal framework element configured to be positioned within the interior volume of a heart and an external framework element configured to be positioned proximate an exterior surface of the heart. The internal framework is flexibly suspended with respect to the external frame. An actuator system is coupled to the framework and configured to engage an exterior surface of the heart. The actuator system comprises an actuator band extending along a portion of a heart wall exterior surface. The actuator band is selectively movable between an actuated state and a relaxed state and is operable, when in the actuated state, to assume a predetermined shape and thereby indent a portion of the heart wall to effect a reduction in the volume of the heart. A drive apparatus is coupled to the actuator band and is operable for selectively moving the actuator band between the relaxed and actuated states to achieve the desired assistance of the natural heart. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,300,414 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,300,414 Tue, 27 Nov 2007 00:00:00 GMT A method of transcranial ultrasound thrombolysis comprises the steps of providing a predetermined level of ultrasonic energy substantially throughout a primary treatment zone encompassing the M1 branch and M2 branches of the middle cerebral artery of an individual. A thrombolytic agent is also administered to the individual. A transcranial ultrasound thrombolysis system (10) is also provided that includes a transducer (20). The transducer is adapted to provide a predetermined level of ultrasonic energy substantially throughout a primary treatment zone encompassing at least a substantial portion of the M1 branch and the M2 branches of the middle cerebral artery in one hemisphere of a brain. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,297,312 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,297,312 Tue, 20 Nov 2007 00:00:00 GMT A simultaneous multianalyte electrochemical assay includes a cell which has a surface and the surface includes analyte binding sites i.e., antibodies or antigens on a solid phase at distinct separate locations. Separate working electrodes are located within proximity to these separate locations. Enzyme labeled antibodies or antigens depending on the assay format are added and the enzyme reaction product measured, by simultaneous amperometric measurement with the independent electrode in each area. The electrodes are spatially separated from adjacent analytes so that a measurement can be taken before cross-interference due to diffusion of product from adjacent analyte areas. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,273,847 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,273,847 Tue, 25 Sep 2007 00:00:00 GMT Methods of treating conditions associated with lipid oxidation or microbial proliferation include the step of administering a composition comprising a pharmacologically effective amount of an antioxidant or antimicrobial lung surfactant protein compound. Peptides derived from lung surfactant protein compounds possess lipid oxidation inhibiting and/or antimicrobial properties. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,273,932 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,273,932 Tue, 25 Sep 2007 00:00:00 GMT The invention relates to antisense oligonucleotides, in particular to antisense oligonucleotides to receptor genes, and the use of such oligonucleotides to regulate reproductive function and as chemopreventive or as a chemotherapeutic for various cancers, especially ovarian cancers. The invention also provides a method for preventing estrogen synthesis, a function of developing ovarian follicles, a therapeutic consideration for the prevention and treatment of some cancers of the breast, endometrium, ovary and cervix and of some endometriosis. The invention also relates to pharmaceutical compositions containing antisense oligonucleotides (ODNs, having 8 to 60 nucleotides) that act by binding to intracellular molecular targets. Optionally, for efficient delivery to a target DNA, RNA or protein, the ODNs may be covalently linked to a carrier moiety, which facilitates delivery of the ODN to the cytosol. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,241,797 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,241,797 Tue, 10 Jul 2007 00:00:00 GMT The invention relates generally to the use of pharmaceutical compositions to increase milk production alone or in combination with certain biological active ingredients. Specifically, the method relates to the use of pharmaceutical compositions that will act on the feedback of the intrinsic regulatory pathway in the mammalian mammary gland. The present invention provides for as a method of increasing bovine milk production as well as a method of correcting certain human lactation abnormalities. Preferably, the compounds used in the methods of the present invention are one or more active agents capable of inhibiting peripheral aromatic amino acid decarboxylase (AADC) enzymes, peripheral tryptophan hydroxylase (TPH) enzymes, peripheral serotonin (5-HT) enzymes, or a combination of enzymes thereof. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,229,756 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,229,756 Tue, 12 Jun 2007 00:00:00 GMT The present invention includes polymorphisms in nucleic acids encoding the alpha-2B adrenergic receptor and expressed alpha-2B adrenergic receptor molecule. The invention also pertains to methods and molecules for detecting such polymorphisms. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment of diseases such as cardiovascular and central nervous system diseases. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,211,386 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,211,386 Tue, 01 May 2007 00:00:00 GMT The present invention includes polymorphisms in nucleic acids encoding the alpha-2A adrenergic receptor and expressed alpha-2A adrenergic receptor molecule. The invention also pertains to methods and molecules for detecting such polymorphisms and transgenic animals expressing alpha-2A adrenergic receptor molecules. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment of diseases such as cardiovascular and central nervous system diseases. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,208,288 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,208,288 Tue, 24 Apr 2007 00:00:00 GMT Methods for enhancing the lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,205,099 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,205,099 Tue, 17 Apr 2007 00:00:00 GMT Methods for studying ion channels comprise incorporating an ion channel onto the surface of a solid-supported membrane; applying a potential to the solid-supported membrane; and measuring an electrical signal of the ion channel. Methods for identifying or screening compounds that bind to ion channels employ an ion channel incorporated onto a solid-supported membrane. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,182,807 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,182,807 Tue, 27 Feb 2007 00:00:00 GMT A method of treating a metal surface by application of a solution containing at least one vinyl silane and at least one bis-silyl aminosilane. A solution composition having at least one vinyl silane and at least one bis-silyl aminosilane is also provided, along with a silane coated metal surface. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,166,627 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,166,627 Tue, 23 Jan 2007 00:00:00 GMT The present invention relates to a process for the production of substituted 5-isoxazolidinone antibiotics. More specifically the patent relates to the production of compounds that mimic the antibiotic action of .beta.-lactams, are resistant to .beta.-lactamase degradation, and inhibit all classes of .beta.-lactamase. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,135,305 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,135,305 Tue, 14 Nov 2006 00:00:00 GMT Methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of lysis-inhibiting amounts of apolipoprotein E4, and methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of a specific level of a lysis-inhibiting agent wherein the specific level is based on the apolipoprotein phenotype of an individual, are provided. Methods for enhancing lysis of coagulated blood by administration of an Apo E peptide fragment to blood containing a clot lysis agent are also provided. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,135,562 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,135,562 Tue, 14 Nov 2006 00:00:00 GMT A recombinant nucleic acid is provided having an avian promoter. One embodiment of the present invention contemplates the use of a gut-specific promoter, wherein a promoter can be the chicken intestinal fatty acid binding protein promoter region. A method for making a transgenic bird is also disclosed by transfecting a bird with a vector comprising a recombinant nucleic acid comprising a chicken intestinal fatty acid binding protein promoter region operably linked to a heterologous nucleic acid expressing a desired polypeptide to be expressed in the gut tissue of an avian. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,125,665 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,125,665 Tue, 24 Oct 2006 00:00:00 GMT The present invention relates to methods and kits for detecting the presence or absence of a target DNA sequence, such as a mutation, within an identified region of a selected DNA molecule, such as a gene. In particular aspects, the invention relates to the use of certain aspects of the polymerase chain reaction ("PCR") and ligase chain reaction ("LCR") techniques for the detection of genetic mutations in genes, particularly point mutations. A kit has been developed for direct EPR detection of specific PCR amplified target nucleic acid sequences. The PCR reaction is carried out in the presence of nitroxide-labeled oligomers that are degraded only if hybridized to a complementary target sequence. The degradation of the nitroxide-labeled oligomers into nitroxide-labeled cleavage products results in a characteristic increase of the h-/ho ratio of the EPR signal; in the absence of a complementary target sequence the EPR signal of nitroxide-labeled oligomer remains unchanged. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,123,796 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,123,796 Tue, 17 Oct 2006 00:00:00 GMT A light emissive display having a specular waveguide that propagates short wavelength light and photoluminescent features adjacent to the waveguide that fluoresce, for example, in visible red, green, blue, and mixed colors when selectively coupled with the short wavelength light. The photoluminescent layers emit light primarily and, therefore, efficiently in the direction of an observer only. This light emissive display may be utilized as a planar light source, as patterned information signage, or as a re-configurable information display containing intensity modulated pixels. The light emissive display may be enhanced optically such that only a small portion of ambient light is reflected from the display while preserving the majority of emitted display luminance. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,118,928 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,118,928 Tue, 10 Oct 2006 00:00:00 GMT Light-emitting devices having a semiconductor phosphor layer formed by metalorganic chemical vapor deposition (MOCVD). The semiconductor phosphor layer may be any Group III nitride semiconductor compound that is in-situ doped during MOCVD deposition with one or more dopants effective to act as luminescent centers. The MOCVD deposition conditions required for the formation of these extrinsic luminescent films differ significantly from the MOCVD deposition conditions utilized to deposit intrinsic GaN luminescent films. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,096,359 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,096,359 Tue, 22 Aug 2006 00:00:00 GMT Strong authentication of packets sent between nodes of different clusters in a two-tier ad hoc network is provided by the cluster heads. Each cluster head authenticates nodes that enter the cluster. Thereafter, when a sending node requests a session from its cluster head with a receiving node in another cluster, the cluster head negotiates a session secret key (SSK) with the corresponding cluster head of the receiving node. Further, the cluster head provides authentication tags for the sending node to use with each packet. Each authentication tag is time-stamped, digitally signed by the cluster head, encrypted with the SSK, and includes indicators of message integrity, including a sequence number and TCP header field of checksum. The sending node further calculates a check result from a number of the authentication tags, encrypted with the SSK, so that the receiving node can authenticate the number of packets. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,087,281 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,087,281 Tue, 08 Aug 2006 00:00:00 GMT The DTF optical memory makes use of the property of dielectric thin film interference to create multi-color pixels and serve as a multi-level optical memory device. The fabrication of the device comprises a dielectric thin film deposited on a substrate that is micro-milled utilizing focused ion beam (FIB) technology. Such micro-milling creates pixels of varying depth that when exposed to a broad-band light source create distinct colors caused by the properties of thin film interference and superposition of reflected light from the broad band source, thus creating an effective optical memory device that may be detected using a color CCD camera or a photo-detector array. Accurate creation and detection of discrete colors allows accurate digital encoding and direct storage of color image in a format of sub-micron pixel array. The robustness of the DTF optical memory device allows operation under harsh environmental conditions, including high temperatures and radiation. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,081,084 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,081,084 Tue, 25 Jul 2006 00:00:00 GMT Abstract An actuation system for assisting the operation of a natural heart is disclosed. The actuation system includes a framework for interfacing with the natural heart and a power system that can be coupled to the framework. The framework includes an internal framework element and an external framework element. The power system is configured to engage an exterior surface of the heart wall, and includes an actuator mechanism for exerting force on the heart wall, a driving mechanism for actuating the actuator mechanism, a transmission mechanism coupled between the actuator mechanism and the driving mechanism for transmitting power to the actuator mechanism, and a carrier device coupled between the actuator mechanism and the driving mechanism and configured for housing the transmission mechanism. The modular power system is configured for being freely exchanged and replaced in the actuation system while leaving the framework elements in place and generally undisturbed. A guide structure such as a wire or tube can also be included for guiding or advancing the power system to its position adjacent to the heart surface. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,065,368 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,065,368 Tue, 20 Jun 2006 00:00:00 GMT Provided is a method for correcting a non-line-of-sight (NLOS) error in a wireless positioning system that enhances the location accuracy of a mobile station by correcting location error caused by NLOS propagation when the mobile station is positioned in a wireless mobile communication environment, and a computer-readable recording medium for recording a program that implements the method. The method checks out the location of the MS in the above environment and provides diverse services by correcting the location error caused by NLOS propagation included in a received signal. That is, a user can enjoy a high-quality location service by receiving the location information only within the radius which user wants, such as traveler's information, vehicle tracking, location service, and location-based advertisements, because the location of the user's MS is detected precisely. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,041,810 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,041,810 Tue, 09 May 2006 00:00:00 GMT The present invention includes polymorphisms in nucleic acids encoding the alpha-2B, alpha-2A, and alpha-2C adrenergic receptor and expressed alpha-2B, alpha-2A and alpha-2C adrenergic receptor molecule. The invention also pertains to methods and molecules for detecting such polymorphisms. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment of diseases such as cardiovascular and central nervous system disease. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,022,296 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,022,296 Tue, 04 Apr 2006 00:00:00 GMT A multiple-field precipitator, flue-gas treating device, in accordance with the principles of the invention, includes a first section having a dual-function, sensible-cooling heat exchanger/electrostatic precipitator, a second section having a wet electrostatic precipitator, and a middle section fluidly connecting the first and second sections. In the first section, the exchanger/precipitator sensibly cools the flue gas and collects most of the dust from the flue gas. In the middle section, the dust-reduced flue gas is combined with an alkaline material, thereby forming reaction products. These reaction products and several other pollutants are captured by the wet electrostatic precipitator, in the form of a pollutant-laden liquid. The pollutant-laden liquid is directed to a series of heat exchangers and settling tanks, where various pollutants such as SO.sub.x, metals, NO.sub.x, and chlorides are removed in different stages. In addition, ammonia is liberated from the pollutant-laden liquid, and circulated back to the middle section, where it is combined with additional dust-reduced flue gas to form additional reaction products for subsequent capture in the wet electrostatic precipitator. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,018,827 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=7,018,827 Tue, 28 Mar 2006 00:00:00 GMT The present invention provides the nucleotide sequence of the M antigen gene of H. capsulatum, which is set forth in the Sequence Listing as SEQ ID NO:1, a nucleic acid having the nucleotide sequence complementary thereto, and nucleic acids having a nucleotide sequence which is substantially the same as the foregoing nucleotide sequences. The present invention also provides vectors and host expressions systems containing the foregoing nucleic acids, and isolated or recombinantly-produced antigens encoded by the foregoing nucleic acids. The present invention further provides antibodies generated against the foregoing antigens, and methods and kits for detecting a previous or current Histoplasma capsulatum infection in a subject, and for diagnosing histoplasmosis. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,988,982 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,988,982 Tue, 24 Jan 2006 00:00:00 GMT An actuation system for assisting the operation of the natural heart includes an actuator element adapted to be positioned proximate a portion of a heart wall. The actuator element is operable for acting on the heart wall portion to effect a change in the shape of the heart. A shape-limiting element is configured for being positioned proximate a heart wall. The shape-limiting element is operable for flexing to assume a curvature no greater than a predetermined curvature when the heart wall is acted upon and maintaining that predetermined curvature to control the shape of the actuated heart. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,972,516 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,972,516 Tue, 06 Dec 2005 00:00:00 GMT An electroluminescent device in which the intensity of the light emission is enhanced by photopumping with radiation from a radiation source of a suitable photon energy. The photopumping radiation from the radiation source interacts with the wide band-gap semiconductor forming the electroluminescent device so as to, when the device is electrically biased to provide light emission, generate additional carriers that enhance the intensity of the light emission from a light-emitting element present in the wide band-gap semiconductor. A waveguide structure may be integrated into a substrate carrying the electroluminescent device for transferring the radiation from the radiation source to the electroluminescent device. Multiple electroluminescent devices may be arranged in pixels for forming a flat panel display in which certain of the devices are photopumped with radiation. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,962,902 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,962,902 Tue, 08 Nov 2005 00:00:00 GMT This invention relates generally to dipeptides and tripeptides and to methods for pharmaceutical treatment of mammals using analogs of such dipeptides and tripeptides. More specifically, the invention relates to tripeptides and their analogs, to pharmaceutical compositions containing such dipeptides and tripeptides and to methods of treatment of mammals using such dipeptides and tripeptides. In addition, the invention relates to methods of treatment of mammals using such dipeptides and tripeptides for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,955,728 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,955,728 Tue, 18 Oct 2005 00:00:00 GMT A method of treating a metal surface by application of a solution containing at least one acyloxy silane and at least one basic compound. A composition having at least one acyloxy silane and at least one basic compound is also provided, along with a silane coated metal surface. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=RE38,773 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=RE38,773 Tue, 09 Aug 2005 00:00:00 GMT The present invention involves the synthesis of a series of amylose (starch) derivatives with various degrees of substitution and amylose/amylopectin ratios. These chains are chemically crosslinked and then mechanically deformed (stretched) to produce a biodegradable and mechanically superior material. Specifically, the process consists of chemically modifying starch into starch derivatives such as starch ethers, starch esters and starch carbamates. The polymers have a percentage degree of substitution of from about 35% to about 95% (degree of substitution is from about 1.05 to about 2.85) and preferably have a percentage degree of substitution of from about 65% to about 90% (degree of substitution is from about 1.95 to about 2.70). The starch derivatives are crosslinked to obtain crosslinked chains and processed into sheets, films, fibers, threads or other articles as known in the art. After processing, the articles are swollen in a thermodynamically acceptable solvent or solvent mixture to a desired volume and deformed in a uniaxial or biaxial extension. The polymers materials are preferably stretched from about 1% to about 500% in the direction of stretching. Finally, the solvent is removed, yielding a homogeneous, highly-ordered material. The present invention improves the properties and the quality of sheets, films, fibers, threads or other articles with respect, for example, to mechanical strength. The materials are developed from starch, a natural renewable source which has low cost, high production levels and which replaces petroleum-based, synthetic polymers; the materials acquire high-strength, high-modulus, toughness and flexibility; and the materials exhibit structural and functional stability during processing, storage and use, yet are susceptible to biodegradation upon disposal. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,925,391 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,925,391 Tue, 02 Aug 2005 00:00:00 GMT A method and apparatus for examining data from a chemical analyzer for artifactual results. A set of rules are established to identify artifactual results based upon experience with the analyzer. Moreover, each rule can be associated with a sample collection or testing problem which potentially caused the artifactual result. Using these rules, output data from the analyzer can be tested to see if any of the rules are satisfied. If a rule is satisfied, then an artifactual result can be indicated, as well as the potential cause of the artifactual result. An output file can be created which indicates the artifactual data samples and the potential artifactual causes. Preferably, the rules are provided in a user-modifiable data file, so that the rules may be modified based upon additional experience. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,925,213 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,925,213 Tue, 02 Aug 2005 00:00:00 GMT A novel fiber optic sensor configuration whose diameter is the same as that of the optical fiber on which it is directly fabricated is introduced. A simple MEMS-compatible fabrication process to accomplish micromachining on the fiber end face has been developed and is detailed. This sensor configuration significantly reduces the size of the sensor and makes the packaging simple and adhesive free. The micromachining process of the present invention also provides for the fabrication of arrays of sensors that would provide two dimensional maps with high spatial resolution of at least one of acoustical vibration, mechanical vibration, pressure, temperature, acceleration, electrostatic fields, magnetic fields or combinations thereof. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,919,469 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,919,469 Tue, 19 Jul 2005 00:00:00 GMT A method of treating a metal substrate by applying a coating of a silane composition having at least one substantially unhydrolyzed aminosilane having one or more secondary or tertiary amino groups. Methods of adhering a polymer (such as rubber) to a metal substrate are also provided. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,912,700 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,912,700 Tue, 28 Jun 2005 00:00:00 GMT A computerized method and system for solving non-linear Boolean equations is disclosed comprising at least partially solving a Boolean function; developing at least one inference regarding said Boolean function and saving said inference to a state machine; and accessing said inference from said state machine to develop at least one heuristic for determining whether said Boolean function is satisfiable. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,905,105 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,905,105 Tue, 14 Jun 2005 00:00:00 GMT An apparatus and method of using the apparatus to prepare a biocompatible biodegradable matrix capable of supporting cells to form an implantable or engraftable surgical device. A matrix-forming fluid is contained within a chamber defined by top and bottom surfaces of a thermally conductive material and spacers defining the thickness of the matrix. The chamber is then cooled to freeze the solution at a controlled rate, resulting in a matrix with a desired and uniform thickness having symmetric and uniform reticulations. The apparatus and method reproducibly forms such a matrix, which may be populated with cells for transplantation and engraftment into a wound. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,861,217 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,861,217 Tue, 01 Mar 2005 00:00:00 GMT A novel polymorphic site in the 5' leader cistron of the .beta..sub.2 -adrenergic receptor (.beta..sub.2 AR) gene is disclosed. The polymorphisms present at this site result in different levels of inhibition of translation of .beta..sub.2 AR mRNA. Compositions and methods for genotyping this polymorphic site as disclosed. In addition, methods for using this genotype information are disclosed, including predicting genetic predisposition to a disease modified by .beta..sub.2 AR expression and predicting a patient's bronchodilating response to .beta..sub.2 -agonists. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,838,240 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,838,240 Tue, 04 Jan 2005 00:00:00 GMT The present invention provides a method for diagnosing Bloom's syndrome (BS) as well as determining whether a subject is a carrier of a mutated BLM gene. The present invention also provides one or more single-stranded nucleic acid probes and antibodies which may be formulated in kits, and used for diagnosing BS or determining whether a human subject is a carrier of a mutated BLM gene. In addition, the present invention provides a method for treating or preventing the onset of BS in a subject in need of such treatment or prevention, as well as vectors and stem cells useful for such treatment or prevention. The present invention also provides a purified and isolated nucleic acid encoding an enzymatically active BLM protein, a vector comprising this nucleic acid, a cell stably transformed with this vector, as well as a method for producing recombinant, enzymatically active BLM protein. A purified, enzymatically active BLM protein is also provided by the present invention. Finally, the present invention provides a vector, an embryonic stem cell, and a non-human, transgenic animal, each of which comprises a mutated BLM gene, as well as a method for producing the non-human, transgenic animal. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,827,981 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,827,981 Tue, 07 Dec 2004 00:00:00 GMT A method of treating a metal surface by application of a solution containing at least one vinyl silane and at least one bis-silyl aminosilane. A solution composition having at least one vinyl silane and at least one bis-silyl aminosilane is also provided, along with a silane coated metal surface. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,824,986 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,824,986 Tue, 30 Nov 2004 00:00:00 GMT The present invention involves techniques for evaluating in vivo cytokine production through the in vivo capture of secreting cytokines by labeled cytokine-binding reagents, followed by in vitro measurement of serum levels of captured cytokine. The methods of the present invention make use of the ability of a neutralizing antibody to a cytokine, when injected into a person or expierimental animal, to bind that cytokine and prevent its catabolism, excretion, or binding to a cytokine receptor. This causes the cytokine, which may normally have a very short in vivo half life, to accumulate in vivo as a cytokine/anti-cytokine antibody complex. If the anti-cytokine antibody is either labeled with a molecule that can be bound by another molecule (e.g.; biotin, which is bound by avidin or streptavidin), or is itself capable of being bound by another molecule (e.g.; a rat anti-cytokine antibody could be bound by an anti-rat immunoglobulin antibody), and the cytokine can also be bound by an antibody that recognizes a site distinct on the cytokine molecule from the site bound by the injected, neutralizing antibody, than the concentration of the cytokine/anti-cytokine complex in serum or other biological fluid can easily be assayed by a modified ELISA. This assay may be used with target analytes other than cytokines, which may include hormones, drugs or other analytes in a human or aninial. The target analyte is preferably a macromolecule, more preferably a protein, and most preferably a cytokine. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,821,425 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,821,425 Tue, 23 Nov 2004 00:00:00 GMT A gravity-flow Biomass Concentrator Reactor (BCR) is provided which uses a porous barrier having pore sizes averaging from about 1 to about 50 microns through which treated water permeates under the pressure of gravity. Solids suspended in water treated with the BCR are effectively retained and concentrated. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,821,799 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,821,799 Tue, 23 Nov 2004 00:00:00 GMT Multi-color light-emissive displays in which the constituent light-emissive devices providing the multiple colors are laterally integrated on the surface of a substrate. The light-emissive devices, typically emitting light by electroluminescence, are arranged such that adjacent devices emit light of a differing wavelength or color. The semiconductor phosphor material forming the active element of each light-emissive device is laterally defined by a lift-off technique in which a patterned layer of a sacrificial material is formed on the substrate, a layer of the semiconductor phosphor material is deposited, and the sacrificial layer is removed to leave semiconductor phosphor material on the substrate in selected locations defined by the pattern. The lift-off technique is iterated to successively fabricate active elements for light-emissive devices of each differing wavelength constituting the multi-color display. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,797,472 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,797,472 Tue, 28 Sep 2004 00:00:00 GMT A method for predicting an individual's response to the .beta.-agonists salmeterol, albuterol, metaproterenol, terbutaline and formoterol is disclosed. Individuals expressing the Ile164 .beta..sub.2 AR variant are likely to exhibit a reduced response as compared to individuals expressing the Thr164 .beta..sub.2 AR variant. The method is useful for making treatment decisions for patients suffering from asthma and chronic obstructive pulmonary diseases. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,797,478 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,797,478 Tue, 28 Sep 2004 00:00:00 GMT Patients having several neurological diseases have been shown to have elevated levels of axonally-derived proteins (i.e. tau and neurofilament proteins) in cerebrospinal fluid (CSF) and in brain tissue. Three monoclonal antibodies (MAbs) recognizing CSF tau proteins were developed. The Mabs were found to label a ladder of 30 kD to 50 kD tau proteins in CSF from patients with disease states producing axonal damage such as head trauma or CNS tumor but not in CSF from controls. High levels of tau protein in CSF were shown to be diagnostic of axonal degeneration in head trauma. An ELISA assay was developed with these MAbs to aid in the diagnosis of patients with axonal damage. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,777,374 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,777,374 Tue, 17 Aug 2004 00:00:00 GMT Organic molecules are partially oxidized in that the gas phase on supported and immobilized photocatalysts deposited having a nanostructure. the photocatalysts are semiconductors such as titanium dioxide and are preferentially coated onto a substrate by flame aerosol coating. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,756,079 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,756,079 Tue, 29 Jun 2004 00:00:00 GMT A method of treating a metal substrate by applying a coating of a silane composition having at least one substantially unhydrolyzed aminosilane having one or more secondary or tertiary amino groups. Methods of adhering a polymer (such as rubber) to a metal substrate are also provided. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,737,408 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,737,408 Tue, 18 May 2004 00:00:00 GMT This invention relates generally to dipeptides and tripeptides and to methods for pharmaceutical treatment of mammals using analogs of such dipeptides and tripeptides. More specifically, the invention relates to tripeptides and their analogs, to pharmaceutical compositions containing such dipeptides and tripeptides and to methods of treatment of mammals using such dipeptides and tripeptides. In addition, the invention relates to methods of treatment of mammals using such dipeptides and tripeptides for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,737,041 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,737,041 Tue, 18 May 2004 00:00:00 GMT Chemical compositions are provided, for use as topical anesthetics or skin refrigerants. These compositions do not cause the depletion of the stratospheric ozone layer and are non-toxic, non-carcinogenic and less flammable than ethyl chloride. Also these chemical compositions match the skin temperature versus time profile needed in the management of myofascial pain syndromes, for effectively freezing skin prior to minor skin surgery and for effectively freezing skin prior to giving painless injections. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,733,510 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,733,510 Tue, 11 May 2004 00:00:00 GMT An insertion kit for positioning a plurality of filaments into muscle includes at least one holder that is configured for being attached to an end portion of the muscle. The holder is coupled with a guide, such as on a frame. The guide conforms the muscle to a desired shape. An inserter, used in conjunction with a plurality of needles, inserts a plurality of filaments into the muscle. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,733,788 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,733,788 Tue, 11 May 2004 00:00:00 GMT A system for delivering solute to a target location within a mammalian body, the system including a medical device, a thermosensitive cellulose gel structure over the medical device, and a biologically active solute within said gel structure. The gel structure deswells and expels the biologically active solute with an increase in gel temperature. The invention includes a method of delivering solute to a target location, where the method includes the steps of providing a thermosensitive cellulose gel structure, wherein the gel structure is loaded with a solute; positioning the loaded gel structure to the target location; and increasing the temperature of the loaded gel structure. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,635,306 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,635,306 Tue, 21 Oct 2003 00:00:00 GMT Light emissive devices incorporating a low-reflectance black or color dielectric layer into their layered structure for improving the contrast of the emitted light. The black or color dielectric layer comprises a layer of a dielectric material having a network of passageways, such as pores or grain boundaries, and a colorant, such as black ink particles of a black ink additive, color ink particles of a color ink additive, or active particles of an organic dye, which is dispersed within the network of passageways. The presence of the colorant in the network of passageways significantly reduces the reflectivity of the dielectric layer. The light emissive devices of the present invention are applicable to improve the display contrast in various flat panel display technologies. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,613,332 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,613,332 Tue, 02 Sep 2003 00:00:00 GMT An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and microencapsulated with a water emulsifiable enteric coating composition. The microcapsules are orally administered. The coating protects the protein as it passes through the stomach. Upon reaching the small intestines, the basic pH of the intestinal juices will dissolve the coating, allowing the protein to be released and induce antigen specific immune response which has the specificity of the native molecule. The stabilizing agent protects the therapeutic protein from denaturation during the encapsulation process. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,592,619 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,592,619 Tue, 15 Jul 2003 00:00:00 GMT An actuation system for assisting the operation of the natural heart comprises a framework for interfacing with a natural heart, through the wall of the heart, which includes an internal framework element configured to be positioned within the interior volume of a heart and an external framework element configured to be positioned proximate an exterior surface of the heart. The internal framework is flexibly suspended with respect to the external frame. An actuator system is coupled to the framework and configured to engage an exterior surface of the heart. The actuator system comprises an actuator band extending along a portion of a heart wall exterior surface. The actuator band is selectively movable between an actuated state and a relaxed state and is operable, when in the actuated state, to assume a predetermined shape and thereby indent a portion of the heart wall to effect a reduction in the volume of the heart. A drive apparatus is coupled to the actuator band and is operable for selectively moving the actuator band between the relaxed and actuated states to achieve the desired assistance of the natural heart. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,589,746 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,589,746 Tue, 08 Jul 2003 00:00:00 GMT Patients having several neurological diseases have been shown to have elevated levels of axonally-derived proteins (i.e. tau and neurofilament proteins) in cerebrospinal fluid (CSF) and in brain tissue. Three monoclonal antibodies (MAbs) recognizing CSF tau proteins were developed. The MAbs were found to label a ladder of 30 kD to 50 kD tau proteins in CSF from patients with disease states producing axonal damage such as head trauma or CNS tumor but not in CSF from controls. High levels of tau protein in CSF were shown to be diagnostic of axonal degeneration in head trauma. An ELISA assay was developed with these MAbs to aid in the diagnosis of patients with axonal damage. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,585,863 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,585,863 Tue, 01 Jul 2003 00:00:00 GMT The present invention relates to the photocatalytic degradation of organic compounds by zeolite and/or mesoporous material hosted photocatalysts. The present invention further relates to a method of treating a contaminated aqueous liquid or gaseous fluid containing organics using a combination of visible or solar light energy in the presence of a photocatalyst to decompose the organic impurities in the liquid or gaseous fluid. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,586,183 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,586,183 Tue, 01 Jul 2003 00:00:00 GMT Genotypes and haplotypes for thirteen polymorphic sites in the .beta..sub.2 -adrenergic receptor (.beta..sub.2 AR) gene are disclosed. Compositions and methods for predicting genetic predisposition to disease associated with polymorphic sites in the (.beta..sub.2 AR) gene, as well as for predicting response to .beta.-agonists, are also disclosed. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,582,375 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,582,375 Tue, 24 Jun 2003 00:00:00 GMT A system for studying a beating explanted heart comprises a fluid inflow circuit configured for coupling to an explanted heart to direct fluid for flowing into a ventricle of the heart, and a fluid outflow circuit configured for coupling to an explanted heart to direct fluid flowing out of the ventricle of the beating heart. A flow meter coupled with the inflow circuit measures the inflow rate of fluid into the heart ventricle and a flow meter coupled with the outflow circuit measures the outflow rate of fluid out of the heart ventricle. A processing system converts the inflow and outflow rates into incremental volume changes in the volume of the heart ventricle and adds and subtracts the incremental volume changes from a relative volume of the heart ventricle to study volume changes in the explanted heart while it is beating. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,569,811 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,569,811 Tue, 27 May 2003 00:00:00 GMT The present invention comprises novel materials comprising composite high-Tc superconductors which contain a dispersion of precipitates and structural defects and thereby exhibit enhanced flux pinning and enhanced critical current in the superconducting state, and novel nanophase orientation processes for their preparation. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,525,808 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,525,808 Tue, 25 Feb 2003 00:00:00 GMT A method and system for determining a spatially local index of refraction in optical materials is provided. Light, including a near-field intensity, is collected above a surface of the material. A probe is oscillated at a plurality of frequencies and in a substantially perpendicular manner relative to the surface of the material to detect the near-field intensity of the light. A distance of the probe from the surface of the material is modulated. Based on a ratio of the near-field intensity of the light detected at the plurality of frequencies, the local index of refraction is determined. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,509,020 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,509,020 Tue, 21 Jan 2003 00:00:00 GMT A promising approach for the therapeutic treatment of brain tumors utilizes replication-competent, neuroattenuated herpes simplex virus-1 (HSV-1) mutants. This approach requires mutation of HSV-1 to eliminate killing of normal, non-dividing cells of the brain (e.g., neurons). The present invention discloses methods for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the gamma 34.5 gene and the uracil DNA glycosylase (UNG) gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and is not neurovirulent. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,498,009 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,498,009 Tue, 24 Dec 2002 00:00:00 GMT The invention concerns polymorphisms in the .beta..sub.1 - and the .beta..sub.2 -adrenergic receptors. The invention also pertains to methods and molecules for detecting such polymorphisms. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment selection for cardiovascular diseases, obesity, and diabetes. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,447,987 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,447,987 Tue, 10 Sep 2002 00:00:00 GMT Novel additive solutions useful for the storage of human red blood cells (RBCs) under refrigerated conditions are disclosed. Also disclosed is a method of using the additive solutions in an appropriate volume to preserve RBCs at about 1 to 6.degree. C. for up to at least about 11 weeks or more. Additive solutions and processes in accordance with the present invention allow the viable storage of human RBCs for an extended period of time in a solution which is directly infusible in humans. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,416,869 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,416,869 Tue, 09 Jul 2002 00:00:00 GMT A method of treating a metal substrate by applying a coating of a silane composition having at least one substantially unhydrolyzed aminosilane having one or more secondary or tertiary groups. Methods of adhering a polymer (such as rubber) to a metal substrate are also provided. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,416,869 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,416,869 Tue, 09 Jul 2002 00:00:00 GMT A method of treating a metal substrate by applying a coating of a silane composition having at least one substantially unhydrolyzed aminosilane having one or more secondary or tertiary groups. Methods of adhering a polymer (such as rubber) to a metal substrate are also provided. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,406,930 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,406,930 Tue, 18 Jun 2002 00:00:00 GMT A visible light emitting device includes a wide band gap semiconductor layer doped with one or more elements which emit light at various wavelengths based upon atomic transitions. The semiconductor preferably is GaN, InN, AIN, BN or alloys thereof doped with a lanthanide element such as Er, Pr or Tm. The light emission can be enhanced by annealing the WBGS. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,387,956 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,387,956 Tue, 14 May 2002 00:00:00 GMT A method of treating an obsessive-compulsive spectrum disorder comprises the step of administering an effective amount of tramadol to an individual. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,372,296 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,372,296 Tue, 16 Apr 2002 00:00:00 GMT The present invention relates to galvanized steel having a high aluminum content in the coating, as well as a batch hot-dip galvanization process for making such steel. The galvanized steel herein has a coating comprising an inner layer of intermetallic iron aluminum compounds, such as Fe.sub.2 Al.sub.5 (which may have some zinc present), and an outer layer of intermetallic zinc aluminum compounds containing from about 17% to about 40% (preferably about 22%, the Zn--Al eutectoid) aluminum (which may have some iron present). The batch hot-dip galvanization process for making such steel comprises: (a) fluxing the steel by electroless plating on the surface of the steel of a metal such as tin, copper or nickel; and (b) dipping the fluxed steel into a molten galvanization bath comprising zinc and from about 17% to about 40% aluminum. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,365,411 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,365,411 Tue, 02 Apr 2002 00:00:00 GMT In the rain forest region of Karnataka State, India, a scandent herb Justicia known as "medicine plant" is widely consumed by the local population by incorporating its extract into desserts. This is especially common in the months of June through August because of the belief that the medicinal properties reach their peak during this season. This plant is now considered to be distributed exclusively in this region of the South Indian rain forest. The plant extract lowers cellular cholesterol and cholesteryl ester concentration. Further studies also showed a novel inhibitory effect on the uptake of ox-LDL by human macrophage cell line. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,365,185 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,365,185 Tue, 02 Apr 2002 00:00:00 GMT The present invention relates to tablets which are time-controlled to release active agent at different rates in different regions of the digestive tract in order to maintain a substantially constant concentration in the blood. In one embodiment, a new modified release drug delivery system, for once a day peroral use, consisting of a solid core comprising an active agent together with a hydrogel, with the solid core being coated with a semi-permeable, self-destructing membrane which is optionally drilled to provide a release orifice, and then optionally further coated with the same or different active agent material. The device delivers the active agent in a substantially constant effective dose for the duration of the transit through the stomach and small intestine, followed by accelerated release when reaching the large intestine. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,365,698 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,365,698 Tue, 02 Apr 2002 00:00:00 GMT Grafted-polysilanes with a greater efficiency for the photoinitiation of vinyl type resins are provided. These grafted polysilanes which include both grafted cyclic polysilanes and grafted networked polysilanes have variable composition and length molecular chains grafted onto the silane backbone which aid in the solubility in vinyl type resins. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,362,471 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,362,471 Tue, 26 Mar 2002 00:00:00 GMT The hazards of exposure to heavy metal contamination, examples of which arsenic, beryllium, lead, cadmium, chromium, nickel, zinc, mercury and barium, and the radioactive substances which deposit in human bone, examples of which are uranium, plutonium, and americium, are very serious and are well known to scientific and medical professionals. Since lead is a prevalent metal contaminant which deposits in human bone, and its effects are quite hazardous, especially to young children, the focus of this disclosure will be on methods of detecting lead exposure. While it is possible to detect the level of lead in the body through the use of a blood test, the relevancy of such tests is limited, since the risk to humans from lead exposure is related to the amount of lead deposited in the bones of the exposed person and not, necessarily, the amount in the blood. Moreover, drawing blood causes some discomfort on the part of the person being tested, which is especially difficult with small children, who are particularly at risk to lead exposure due to various environmental factors. Accordingly, an alternative method, the indirect measure of the level of cumulative lead exposure in the bones of a person by sue of x-ray fluorescence, is often employed. This invention relates generally to surrogate structures, or phantoms, that exhibit radiological properties of bone, muscle, and other soft tissue. Specifically, this invention relates to phantoms which have been designed to accurately exhibit anthropometric and radiological properties of human bone and soft tissue for use in calibrating the response of spectroscopic instruments that enable in vivo measurement of the levels of contamination from stable metals and radioactive material. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,344,121 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,344,121 Sat, 05 Jan 2002 00:00:00 GMT The methods of the present invention address a critical need for the development of preparative chiral separations. These include preparative chiral separation methods based on continuous electrophoresis using a chiral additive in the buffer. The application of continuous free flow electrophoresis to bulk scale aqueous chiral separations is novel and has the potential for obtaining mg to g/hour quantities of both pure enantiomers of chiral drugs in aqueous solution, with wide applicability for a broad range of chiral drugs from many different categories as well as chiral intermediates or metabolites. The present methods allow for the potential recovery and reuse of the chiral selector (typically expensive and/or rare). Although continuous free flow electrophoresis has been used primarily for the separation of biopolymers, its use for the separation of small molecules has remained relatively unexplored. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,335,169 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,335,169 Tue, 01 Jan 2002 00:00:00 GMT Eukaryotic cells have evolved a mechanism that delays the onset of anaphase until chromosomes are properly positioned on the spindle. To understand the molecular basis of such surveillance mechanism in human cells, we have cloned a full-length cDNA encoding a putative mitotic checkpoint kinase termed hBub1. Sequence comparison reveals that hBub1 is a structurally conserved protein, sharing 23% amino acid residue identity with BUB1 of budding yeast. In addition, the N-terminal portion (161 amino acids) of hBub1 shows a significant homology to yeast MAD3, a protein also known to be involved in the mitotic checkpoint response pathway. Northern blot analyses show that hBub1 mRNA level is abundantly expressed in tissues or cells with a high mitotic index. When Dami cells undergoes terminal differentiation following treatment with phorbol ester, hBub1 expression in this cell line is rapidly downregulated. The hBub1 protein level is low in G1 and remains relatively constant in S, G2 and M phases. Immunofluorescence analysis shows that hBub1 protein co-localizes with a centromere-kinetochore antigen CREST in interphase, mitotic prophase and nocodazole-treated cells. Antibody electroporation experiments show that hBub1 is an important component of the spindle checkpoint pathway. Furthermore, fluorescence in situ hybridization analysis maps the hBub1 gene to chromosome 2q12-13. Our studies suggest that hBub1 expression is restricted to proliferating cells and appears to be involved in regulating cell-cycle progression. The molecular cloning of hBub1 cDNA will facilitate the study of its role in spindle checkpoint control as well as its potential role in certain genetic disorders. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,328,967 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,328,967 Tue, 11 Dec 2001 00:00:00 GMT A microsphere containing an immunogen bound to an inert particle having a mesh size of greater than about 35 mesh for site-specific release and induction of an immune response. The immune response may be an overall enhanced T lymphocyte immune response or a selective response. The physical and chemical characterigticg and/or modes of administration of the microsphere may be engineered to increase T.sub.H 1 lymphocytes for treatment of cancer or infectious disease. The microencapsulated immunogen has an enteric coating for oral administration. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,323,236 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,323,236 Tue, 27 Nov 2001 00:00:00 GMT Impulse Control Disorders (ICD's) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others. The present invention comprises methods for the treatment or prevention of ICD's using a class of sulfamates of the following formula: ##STR1## wherein X is CH.sub.2 or oxygen, and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as herein defined. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention are also disclosed. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,300,121 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,300,121 Tue, 09 Oct 2001 00:00:00 GMT Bioavailability of lead and other heavy metals in the environment may be reduced by addition of microorganisms which sequester lead from the environment in the presence of phosphate. The microorganisms are highly mobile and are, therefore, capable of scavenging a material for lead, which they then sequester. The method basically consists of reducing bioavailability of lead in the environment by addition of Pseudomonas aeruginosa strain CHL004 (ATCC 55937) to said environment in the presence of phosphate which contains at least stoichiometric equivalent amounts of phosphate to lead. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,277,874 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,277,874 Tue, 21 Aug 2001 00:00:00 GMT Methods for treating diseases associated with toxicity of Apolipoprotein E ("apoE"). Specifically, the present invention relates to new methods for treating a mammal having a condition associated with toxicity of apolipoprotein E cleavage fragments containing residues 130-169, comprising administering to said mammal a pharmacologically effective amount of compound or a pharmaceutically acceptable sale, derivative or fragment thereof to interfere with the receptor-binding site associated with residues 130-169 of the apolipoprotein E molecule in said mammal. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,261,638 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,261,638 Tue, 17 Jul 2001 00:00:00 GMT A method of treating a metal substrate by applying a first coating treatment solution of 0.1% by volume of at least one silane, wherein the silane consists only of a multi-functional silane having at least two trisubstituted silyl groups, wherein the substituents are individually chosen from the group consisting of alkoxy and acetoxy, and wherein the multi-functional silane has been at least partially hydrolyzed and wherein the first coating treatment solution has a pH of less than about 7. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,258,263 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,258,263 Tue, 10 Jul 2001 00:00:00 GMT A chromatograph fabricated using microelectromechanical techniques. The chromatograph includes a first layer superimposed over a second layer. At least one micro-channel is etched into the second layer to provide the separation column of the chromatograph. The surfaces of the micro-channel are chemically activated in order to separate the components of a sample flowing through the micro-channel by bonded phase chemistry. A third layer is placed in superimposed relationship with the second layer. At least one pair of electrodes is formed to the third layer with at least a portion of the electrodes internal to the micro-channel of the second layer. The electrodes detect separated components flowing through the micro-channel and identify them by their electrical conductivity. The depth of the micro-channel is greater than the width, thereby minimizing pressure drop across the device and allowing the chromatograph to operate with a high degree of speed, sensitivity and accuracy. Good resolution is obtained with narrow integrated electrodes for sensing the separated components of the sample. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,254,940 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,254,940 Tue, 03 Jul 2001 00:00:00 GMT The present invention related to methods of manufacturing oxide, nitride, carbide, and boride powders and other ceramic, organic, metallic, carbon and alloy powders and films and their mixtures having well-controlled size and crystallinity characteristics. This invention relates, more particularly, to a development in the synthesis of the ceramic, metallic, composite, carbon and alloy nanometer-sized particles with precisely controlled specific surface area, or primary particle size, crystallinity and composition. The product made using the process of the present invention and the use of that product are also claimed herein. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,255,669 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,255,669 Tue, 03 Jul 2001 00:00:00 GMT A visible light emitting device includes a wide band gap semiconductor layer doped with one or more elements which emit light at various wavelengths based upon atomic transitions. The semiconductor preferably is GaN, InN, AIN, BN or alloys thereof doped with a lanthanide element such as Er, Pr or Tm. The light emission can be enhanced by annealing the WBGS. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,248,217 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,248,217 Tue, 19 Jun 2001 00:00:00 GMT This invention is directed to a process for forming a sorbent-metal complex. The process includes oxidizing a sorbent precursor and contacting the sorbent precursor with a metallic species. The process further includes chemically reacting the sorbent precursor and the metallic species, thereby forming a sorbent-metal complex. In one particular aspect of the invention, at least a portion of the sorbent precursor is transformed into sorbent particles during the oxidation step. These sorbent particles then are contacted with the metallic species and chemically reacted with the metallic species, thereby forming a sorbent-metal complex. Another aspect of the invention is directed to a process for forming a sorbent metal complex in a combustion system. The process includes introducing a sorbent precursor into a combustion system and subjecting the sorbent precursor to an elevated temperature sufficient to oxidize the sorbent precursor and transform the sorbent precursor into sorbent particles. The process further includes contacting the sorbent particles with a metallic species and exposing the sorbent particles and the metallic species to a complex-forming temperature whereby the metallic species reacts with the sorbent particles thereby forming a sorbent-metal complex under UV irradiation. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,245,751 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,245,751 Tue, 12 Jun 2001 00:00:00 GMT Methods for treating diseases associated with toxicity of Apolipoprotein E ("apoE"). Specifically, the present invention relates to new methods for treating a mammal having a condition associated with toxicity of apolipoprotein E cleavage fragments containing residues 130-169, comprising administering to said mammal a pharmacologically effective amount of compound or a pharmaceutically acceptable sale, derivative or fragment thereof to interfere with generation of toxic fragments of apolipoprotein E or with the receptor-binding site associated with residues 130-169 of the apolipoprotein E molecule in said mammal. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,235,718 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,235,718 Tue, 22 May 2001 00:00:00 GMT This invention relates generally to dipeptides and tripeptides and to methods for pharmaceutical treatment of mammals using analogs of such dipeptides and tripeptides. More specifically, the invention relates to tripeptides and their analogs, to pharmaceutical compositions containing such dipeptides and tripeptides and to methods of treatment of mammals using such dipeptides and tripeptides. In addition, the invention relates to methods of treatment of mammals using such dipeptides and tripeptides for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,221,643 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,221,643 Tue, 24 Apr 2001 00:00:00 GMT The present invention provides a method for diagnosing BS as well as determining whether a subject is a carrier of a mutated BLM gene. The present invention also provides one or more single-stranded nucleic acid probes and antibodies which may be formulated in kits, and used for diagnosing BS or determining whether a subject is a carrier of a mutated BLM gene. In addition, the present invention provides a method for treating or preventing the onset of BS in a subject in need of such treatment or prevention, as well as vectors and stem cells useful for such treatment or prevention. The present invention also provides a purified and isolated nucleic acid encoding an enzymatically active BLM protein, a vector comprising this nucleic acid, a cell stably transformed with this vector, as well as a method for producing recombinant, enzymatically active BLM protein. A purified, enzymatically active BLM protein is also provided by the present invention. Finally, the present invention provides a vector, an embryonic stem cell, and a non-human, transgenic animal, each of which comprises a mutated BLM gene, as well as a method for producing the non-human, transgenic animal. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,221,103 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,221,103 Tue, 24 Apr 2001 00:00:00 GMT A geometric reconfiguration assembly for the natural heart having a collar configured for surrounding the natural heart. The collar can include a plurality of bands, such as thin bands of about 0.2 mm in thickness, in a spaced relationship to each other, and a connector bar intersecting the plurality of bands and configured for maintaining the spaced relationship of the bands to each other. The collar may include a plurality of bands, such as from about 2 to about 10 bands, that are positioned parallel to each other. The bands can each be made of a biomedical material, such as polyacetal or a metal, such as titanium or steel. The connector bar of the present invention can be positioned tangential to the plurality of bands, and may have a plurality of grooves configured to receive the thickness of each of the plurality of bands. The grooves also may be beveled to allow for the bands to flex as the heart beats. The connector bar's inner surface can have an outwardly convex curved configuration, and may even include a cushioned portion that can be made from a polymeric material. A pad may be positioned between the collar and the epicardial surface of the heart that may comprise a low durometer polymer, or either a gel-filled cushion or a fluid-filled cushion. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,214,308 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,214,308 Tue, 10 Apr 2001 00:00:00 GMT A two stage method is described for the removal of NO.sub.x and SO.sub.x from flue gas. The first stage removes all NO.sub.x by sodium sulfite sorbent injection. The second stage removes SO.sub.x by sodium bicarbonate injection. The sodium sulfite product formed in the second stage is transferred to the first stage for injection. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,214,047 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,214,047 Tue, 10 Apr 2001 00:00:00 GMT A prosthetic linkage for use with skeletal muscle. The linkage includes a plurality of longitudinally extending filaments forming a strand. The strand has a first portion that includes a core portion wherein the filaments extend generally parallel to each other, and an exterior portion wherein the filaments are braided along its longitudinal axis around the core portion. The strand also includes a second portion wherein the filaments are generally randomly oriented and sized for integration into skeletal muscle. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,210,700 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,210,700 Tue, 03 Apr 2001 00:00:00 GMT Abstract An improved immunomodulatory therapy for enhancement of depressed host defense mechanisms and improving allograft survival rates comprising the use of omega-9 unsaturated fatty acids to alter the immune response associated with organ transplantation. It is administered optionally in conjunction with an immunomodulatory diet comprising arginine and its salts, or metabolic precursors of arginine, together with an immuno-suppressive treatment comprising the administration of cyclosporine or other immuno-suppressants and optionally, with or without a donor specific transfusion. An especially preferred source of the omega-9 unsaturated fatty acids is canola oil. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,200,636 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,200,636 Tue, 13 Mar 2001 00:00:00 GMT An improved fluxing method for the galvanization of steel, particularly batch galvanization, is disclosed. In this process, a metallic element is deposited (for example, by electroless plating) on the surface of the steel sheet or other article prior to its being dipped in the galvanization bath. Preferred metals for use in this fluxing process are tin, copper, nickel, with tin being more preferred, and mixtures of copper and tin being most preferred. This metallic film layer has a thickness between about 5 and about 50 nm. The process of the present invention provides a number of benefits when compared to conventional fluxing processes: for example, it is compatible with the inclusion of aluminum in the galvanization bath; it permits a greater time delay between the fluxing and galvanization operations; and it eliminates the formation of hydrogen chloride or other toxic fumes when the fluxed article is dipped in the molten zinc galvanization bath. Additionally, the present process permits the combination of the fluxing and pickling steps into a single step, providing a shorter and more efficient galvanization process than is conventionally used. The fluxing method may also be used in a continuous galvanization process. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,190,408 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,190,408 Tue, 20 Feb 2001 00:00:00 GMT A static device for use with the heart that has a plurality of members configured to be positioned adjacent the epicardial surface of the heart. The members are joined by at least one connector wherein the members are fixed in a spatial or spaced relationship relative to each other such that a portion of the heart wall is displaced inwardly. The member(s) can be configured in a rectangular shape, and preferably includes an inner surface having a curved configuration. In one embodiment, the device can have first and second member that are positioned in a spaced relationship relative to each other about 180 degrees apart. The first member is configured to be positioned adjacent the anterolateral surface of the chamber, and the second member configured to be positioned adjacent the posteromedial surface of the chamber. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,190,408 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,190,408 Tue, 20 Feb 2001 00:00:00 GMT A static device for use with the heart that has a plurality of members configured to be positioned adjacent the epicardial surface of the heart. The members are joined by at least one connector wherein the members are fixed in a spatial or spaced relationship relative to each other such that a portion of the heart wall is displaced inwardly. The member(s) can be configured in a rectangular shape, and preferably includes an inner surface having a curved configuration. In one embodiment, the device can have first and second member that are positioned in a spaced relationship relative to each other about 180 degrees apart. The first member is configured to be positioned adjacent the anterolateral surface of the chamber, and the second member configured to be positioned adjacent the posteromedial surface of the chamber. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,174,529 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,174,529 Tue, 16 Jan 2001 00:00:00 GMT An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and microencapsulated with a water emulsifiable enteric coating composition. The microcapsules are orally administered. The coating protects the protein as it passes through the stomach. Upon reaching the small intestines, the basic pH of the intestinal juices will dissolve the coating, allowing the protein to be released and induce antigen specific immune response which has the specificity of the native molecule. The stabilizing agent protects the therapeutic protein from denaturation during the encapsulation process. In addition to being immunogenic, when administered orally, encapsulated allergen has a therapeutic effect in the treatment of human allergies. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,165,785 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,165,785 Tue, 26 Dec 2000 00:00:00 GMT A method of treatment using immune system suppressor cells and immune system stimulator cells comprises providing stem cells; combining the stem cells with lymphoid-derived cells to produce a co-culture; adding lipopolysaccharide and a factor selected from the group consisting of granulocyte macrophage-colony stimulating factor, macrophage colony stimulating factor, granulocyte-colony stimulating factor and mixtures thereof to the co-culture; obtaining immune system suppressor cells and immune system stimulator cells from the co-culture; and introducing and the cells into a host. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,162,547 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,162,547 Tue, 19 Dec 2000 00:00:00 GMT A method of preventing corrosion of metals using bis-functional polysulfur silanes. The method includes providing a metal surface, and applying a treatment solution onto the metal surface. The treatment solution includes at least one hydrolyzed bis-functional polysulfur silane of the formula: ##STR1## wherein each R is an alkyl or an acetyl group, and Z is either --S.sub.x or --Q--S.sub.x --Q--, wherein each Q is an aliphatic or aromatic group, and x is an integer of from 2 to 9. A treatment solution and metal surface having improved corrosion resistance are also provided. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,160,015 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,160,015 Tue, 12 Dec 2000 00:00:00 GMT The present invention relates to compositions useful in the treatment of benign proliferative disorder neurofibromatosis comprising a farnesyl protein transferase inhibitor. Further contained in this invention are methods of treating benign proliferative disorder neurofibromatosis in a mammal, which methods comprise administering to said mammal, a farnesyl protein transferase inhibitor. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,159,968 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,159,968 Tue, 12 Dec 2000 00:00:00 GMT This invention provides a method for increasing the permeability of epithelial cells to a chloride ion in a subject comprising administering a permeability enhancing amount of a composition comprising a specifically-defined nontoxic, benzimidazole or benzimidazole derivative. The invention also relates to a method of treating cystic fibrosis comprising administering an epithelial cell chloride permeability enhancing amount of a composition comprising a specifically-defined nontoxic, benzimidazole or benzimidazole derivative. The benzimidazole compound having chloride channel activation activity for use in this invention includes a 2-[(pyridyl)-methylsulfinyl or -methylthio]benzimidazole derivatives and salts thereof, for instance. Specifically, these include the compounds omeprazole, lansoprazole, thimoprazole and pantoprazole. When appropriately applied, these compounds can correct detective chloride transport, increasing the salt and water flux in diseased tissues to levels closer to those of normal tissues thus reducing life-threatening complications. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,150,085 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,150,085 Tue, 21 Nov 2000 00:00:00 GMT Novel additive solutions useful for the storage of human red blood cells (RBCs) under refrigerated conditions are disclosed. Also disclosed is a method of using the additive solutions in an appropriate volume to preserve RBCs at about 1 to 6.degree. C. for up to 10 weeks. Additive solutions and processes in accordance with the present invention allow the viable storage of human RBCs for an extended period of time in a solution which is directly infusible in humans. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,127,320 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,127,320 Tue, 03 Oct 2000 00:00:00 GMT Thixotropic, lubricious coatings are provided on the web or surface area surrounding a valve slit or the like in medical, needleless coupling sites. The coating comprises a combination of fluorinated polyalkyl ether and a thixotropic agent such as fumed silica. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,116,863 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,116,863 Tue, 12 Sep 2000 00:00:00 GMT A microactuated device and method of making the same in which an electromagnetic driver, overlapping a magnetically permeable diaphragm, is utilized to drive the microactuated device. Through the use of an electromagnetic driver to provide the motive force for a microactuated device, exceptional performance may be realized, e.g., with a substantially reduced drive voltage for micropumps, microvalves, and the like, and with stronger and more precise sensory outputs for microactuated sensors and the like. Moreover, by overlapping the electromagnetic driver over a diaphragm, a number of batch processing techniques, each of which is well suited for mass production, may be used in the fabrication of extremely compact and cost effective integrated devices. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,117,328 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,117,328 Tue, 12 Sep 2000 00:00:00 GMT Pervaporation membranes are used for removing volatile organic compounds from wastewaters. These pervaporation membranes are prepared by dispersing at least one hydrophobic adsorbent such as activated carbon uniformly into a polymer matrix. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,100,457 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,100,457 Tue, 08 Aug 2000 00:00:00 GMT An improved string arrangement for coupling one or more of strings to a sound radiating member, such as a soundboard, is provided having a bridge structure with a rib with a bridge face and a bearing point edge. Associated with each string and disposed at least tangent to the bearing point edge and substantially perpendicular to the bridge face is a first bridge pin. A second and/or third bridge pin may also be provided axially behind the first bridge pin for retaining each string against the bridge face. This invention provides enhanced tone quality by improving sustain and amplitude of fundamental frequencies in a convenient and simple structural arrangement for pianos and other stringed devices. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,077,567 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,077,567 Tue, 20 Jun 2000 00:00:00 GMT A silica coated substrate comprises a substrate having a zinc containing surface. A plasma polymerized coating is adhered to the surface. The coating consists essentially of silicon and oxygen and contains minimal amounts of carbon. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,054,633 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,054,633 Tue, 25 Apr 2000 00:00:00 GMT Novel transgenic nonhuman animals, such as transgenic mice, for detecting and characterizing mutations in vivo are disclosed. When detecting reverse mutations, such as mutations of the APRT gene, the transgenic nonhuman animal now afford the unique advantage of detecting and characterizing mutations in vivo without having to sacrifice the animals as required heretofore. Moreover, since the transgenic nonhuman animals do not need to be sacrificed, they provide the unique opportunity to correlate the incidence and location of tumors (carcinogenesis) with the incidence and location of mutagenesis. Also disclosed are novel constructs, cell lines and chimeric animals for producing the novel transgenic animals. Novel methods for detecting and characterizing the mutations in vivo and producing animals for use in accordance with the methods of the instant invention are disclosed. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,046,167 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,046,167 Tue, 04 Apr 2000 00:00:00 GMT The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,032,076 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,032,076 Tue, 29 Feb 2000 00:00:00 GMT Extra- to intra-corporeal power is provided by a transformer implanted at least partially within a defunctionalized intestinal pouch (or sack), such as an ileal pouch. The transformer includes a continuous loop magnetic core which is implanted within the pouch. The pouch itself includes a passageway permitting the secondary wiring to extend around the and through the magnetic core and through its central opening without entering the pouch providing intracorporeal current. Wire providing the primary windings extend from outside the body in through a stoma into the pouch and surround portions of the magnetic core within the pouch. Because of the use of a generally continuous loop magnetic core of high permeability, there is little or virtually no magnetic flux leakage. A solid circular core of a high permeability material may be used. In an alternate embodiment of the present invention the magnetic core can be divided into two separate portions, one implanted within the pouch and one implanted within the peritoneum adjacent the pouch so that the two core portions combine to form a generally continuous loop magnetic path, separated only by the intestinal wall of the pouch. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,027,795 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,027,795 Tue, 22 Feb 2000 00:00:00 GMT An absorbent, microporous foam comprising a crosslinked polymer having interconnected fluid cells distributed throughout its mass, wherein the fluid cells have a diameter of between about 0.1 and about 100 .mu.m, and wherein the foam can rapidly absorb at least about twice its dry weight in fluid, is disclosed. Also disclosed is a method for producing such microporous, absorbent foams. In this method: (a) a crosslinkable polymer and a first solvent are mixed to form a stable solution which can be induced to phase separate; (b) the stable solution is induced to phase separate into a polymer concentrated phase and a polymer dilute phase; (c) the polymer is induced to crosslink in the polymer concentrated phase for a predetermined period of time thereby forming a microporous material; and (d) the microporous material is dried to produce the absorbent foam. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,022,865 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,022,865 Tue, 08 Feb 2000 00:00:00 GMT A stable aqueous solution having high concentrations of both biologically available calcium and biologically available phosphate is provided by combining phosphate and calcium ions in the aqueous solution wherein the phosphate is in the form of a saccharide phosphate and preferably a monosaccharide diphosphate. Preferred solutions include fructose 1,6-diphosphate, glucose diphosphate, sucrose diphosphate and so on. This is particularly suitable for providing calcium and phosphate ions in a total parenteral nutrition solution. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,018,058 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,018,058 Tue, 25 Jan 2000 00:00:00 GMT The present invention relates to a class of 1,4-dihydrodioxin masked quinone compounds which are useful as DNA or RNA cleaving reagents. These compounds may additionally include moieties which target the compounds to specific base sequences on the DNA or RNA molecule to permit site-specific cleavage. The process for using these compounds in a UV or short wavelength visible light-activated reaction for cleaving DNA, as well as pharmaceutical compositions containing these compounds, are also disclosed. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,015,828 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,015,828 Tue, 18 Jan 2000 00:00:00 GMT This invention relates generally to medical treatment methods. Specifically, the invention relates to methodology for the correction of defective chloride transport by activation of chloride channels of the lung and other epithelia using genetic or chemical modification. These methods relate to the treatment of epithelia with compounds which cause activation of the channel as measured by increased probability (Po) of opening of the channel at physiologically relevant holding potentials. These methods also relate to the treatment of epithelia with gene therapy to introduce chloride channels genes with site mutations which cause activation of the channel as measured by increased probability (Po) of opening of the channel at physiologically relevant holding potentials. These treatments will reduce life-threatening complications frequently found in diseases such as cystic fibrosis. These methods of activation of chloride channels also comprise treatment of chloride channels with amidation reactions. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,013,633 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=6,013,633 Tue, 11 Jan 2000 00:00:00 GMT http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,958,873 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,958,873 Tue, 28 Sep 1999 00:00:00 GMT The invention is directed to lanthocin-containing tablet formulations for oral administration. The inventive formulations afford delivery of the lanthocin to the colon in amounts sufficient to treat diseases brought on by bacterial infection of the colon. Also provided is a process for preparation of the formulations. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,957,977 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,957,977 Tue, 28 Sep 1999 00:00:00 GMT An activator device for activation of cardiac tissue having a stint for placement within the interior volume of a natural heart adjacent cardiac tissue thereof. The device also includes a yoke for placement around a portion of the exterior surface of the natural heart in general alignment with the stint and connected to the stint by at least one cord. The device provides a simple yet reliable mechanism for assisting in extended activation of a natural heart with minimal impact and intrusion. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,946,471 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,946,471 Tue, 31 Aug 1999 00:00:00 GMT An improved laboratory instrument emulation network system is provided having instrument emulation stations and an instrument emulation network controller in which the emulation network system allows communication between the network controller and each instrument emulation station along a bi-directional, high-speed serial data communications network. The network system allows users at each emulation station to configure the station so as to emulate a certain instrument, i.e., voltmeter, pH meter, temperature meter, etc. The system performs real-time acquisition of raw data at each emulation station, transmits the raw data to the network controller in near-real time where it is converted into engineering units (e.g., volts, units of pH, degrees Celsius), then returns the converted data to the respective station and displays the data in either graphical or numerical format (or both), as the user selects. The converted data can also be transmitted to other emulation stations, if desired. A personal computer can be connected into the system to transfer data and software, in which laboratory station configuration software can be downloaded from the personal computer, and acquired data can be uploaded from the network controller. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,913,243 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,913,243 Tue, 15 Jun 1999 00:00:00 GMT An ultrasonic transducer for use in nondestructive testing includes a multi-transducer array mounted on a wedge, the wedge including a surface substantially contoured to conform to a sensing surface to be tested. At least the surface is covered by a silicone rubber material cast as a tubular sleeve which has the following properties: tensile strength--600 psi tear strength--135 psi sound velocity--1,000 m/s density--1,200 kg/m.sup.3 Shore A Durometer--16. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,869,802 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,869,802 Tue, 09 Feb 1999 00:00:00 GMT A plasma producing device is furnished with a half height waveguide that transmits microwave energy through a window into an evacuated chamber, adjustable spacers controlling the distance between an opening of the waveguide and the window, and/or a return piece adjacent a permanent magnet producing the required magnetic field, preferably including sidewalls encompassing the permanent magnet. The improvements promote plasma uniformity at the workpiece by allowing smaller magnets to be employed, reducing stray magnetic fields outside the resonance zone, and facilitating transition of the microwaves from a rectangular transmission mode to a circular transmission mode outside the chamber. Facilitating transistion in this manner improves tuning or impedance matching. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,861,132 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,861,132 Tue, 19 Jan 1999 00:00:00 GMT A gas phase process for the production of titanium dioxide powders having well-controlled crystalline and surface area characteristics is disclosed. In this process, which is preferably carried out in a laminar diffusion flame reactor, vapor phase TiCl.sub.4 and oxygen are mixed in a reaction area which is heated externally. The titanium dioxide powder formed is then collected. It is preferred that the heat source used be a hydrocarbon fueled (e.g., methane) flame. Optionally, a vapor phase dopant (such as SiCl.sub.4) may be added to the reaction mixture to desirably affect the physical properties of the titanium dioxide produced. In a particularly preferred embodiment, a corona electric field is positioned across the area where the combustion reaction takes place (i.e., the reaction area). High anatase, high surface area titanium dioxide powders made by this process are excellent photocatalysts. The products of this process and the use of those products as photocatalysts are also disclosed. This process is also useful for producing other ceramic powders (such as silicon dioxide and tin oxide), as well as pure metallic or alloy powders. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,824,501 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,824,501 Tue, 20 Oct 1998 00:00:00 GMT The present invention provides a method for diagnosing BS as well as determining whether a subject is a carrier of a mutated BLM gene. The present invention also provides one or more single-stranded nucleic acid probes and antibodies which may be formulated in kits, and used for diagnosing BS or determining whether a subject is a carrier of a mutated BLM gene. In addition, the present invention provides a method for treating or preventing the onset of BS in a subject in need of such treatment or prevention, as well as vectors and stem cells useful for such treatment or prevention. The present invention also provides a purified and isolated nucleic acid encoding an enzymatically active BLM protein, a vector comprising this nucleic acid, a cell stably transformed with this vector, as well as a method for producing recombinant, enzymatically active BLM protein. A purified, enzymatically active BLM protein is also provided by the present invention. Finally, the present invention provides a vector, an embryonic stem cell, and a non-human, transgenic animal, each of which comprises a mutated BLM gene, as well as a method for producing the non-human, transgenic animal. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,783,193 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,783,193 Tue, 21 Jul 1998 00:00:00 GMT An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and microencapsulated with a water emulsifiable enteric coating composition. The microcapsules are orally administered. The coating protects the protein as it passes through the stomach. Upon reaching the small intestines, the basic pH of the intestinal juices will dissolve the coating, allowing the protein to be released and induce antigen specific immune response which has the specificity of the native molecule. The stabilizing agent protects the therapeutic protein from denaturation during the encapsulation process. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,759,629 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,759,629 Tue, 02 Jun 1998 00:00:00 GMT A method of preventing corrosion of a metal sheet, comprising the steps of: providing a metal sheet chosen from the group consisting of coated steel sheet, aluminum sheet and aluminum alloy sheet; and applying a solution containing at least one hydrolyzed vinyl silane to the metal sheet. A coating of paint or other polymer may be applied directly on top of the vinyl silane coating. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,759,908 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,759,908 Tue, 02 Jun 1998 00:00:00 GMT A method is disclosed for forming crystalline silicon carbide (SiC) semiconductors on a semiconductor-on-insulator (SOI) structure. In this method, the thin silicon layer of an SOI substrate is converted to silicon carbide using a carbonization reaction. The SiC layer is then, optionally, further increased in thickness using a vapor deposition reaction, preferably using a silicon-containing cyclobutane gas. Rather than increasing the thickness of the SiC layer, the vapor deposition process can also be used to deposit a layer of another semiconductor (e.g., a III-N or III-P semiconductor) on the thin SiC layer. The products made by this process are also claimed. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,750,197 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,750,197 Tue, 12 May 1998 00:00:00 GMT A method of preventing corrosion of metals using silanes. The method comprises applying a first treatment solution directly onto the surface of the metal, wherein the first treatment solution contains at least one multi-functional silane having at least two trisubstituted silyl groups, and wherein the substituents are individually chosen from the group consisting of alkoxy and acetoxy. An optional second treatment solution containing an organofunctional silane may also be employed, particularly if the metal is to be painted. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,746,895 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,746,895 Tue, 05 May 1998 00:00:00 GMT A component of an aluminum production cell, in particular a cathode or a cell lining of an electrolytic cell for the production of aluminum by the electrolysis of alumina in cryolite, having an aluminum-wettable refractory coating on a heat-stable baked carbon-containing body, is produced from a part-manufactured cell component which is a layered composite of two precursors. A precursor layer of the aluminum-wettable refractory coating contains at least one aluminum-wettable refractory material in particulate form, or a particulate micropyretic reaction mixture which, when ignited, reacts to form at least one aluminum-wettable refractory material, or a mixture thereof, and non-carbon fillers and binders. A non-baked or part-baked precursor of the heat-stable carbon-containing body comprises particulate carbon compacted with a heat-convertible binder which when subjected to heat treatment binds the particulate carbon into the heat-stable carbon-containing body of the fully-manufactured cell component. This layered composite is convertible to the fully-manufactured cell component by heat treatment to form the aluminum-wettable refractory coating and simultaneously bind and heat-stabilize the carbon-containing body. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,728,466 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,728,466 Tue, 17 Mar 1998 00:00:00 GMT A cathode block of a cell for the electrowinning of aluminium comprises a carbon body having a hard and abrasion-resistant surface obtained by heating an applied layer of particulate refractory hard metal boride with a bonding material which when heated reacts with the refractory hard metal boride and with carbon. In particular a slurry of particulate refractory boride in colloidal alumina is dried and heated under an inert or a reducing atmosphere, formed by a bed of carbon powder, and reacted to form at least one stable compound between aluminium derived from colloidal alumina; boron and titanium derived from the titanium diboride; and carbon from the reducing atmosphere. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,719,126 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,719,126 Tue, 17 Feb 1998 00:00:00 GMT A purified, naturally derived melanogenic inhibitor protein capable of inhibiting melanogenesis in pigmentary cells has an amino acid sequence SEQ ID NO: 4. A method of producing melanogenic inhibitor protein comprises grafting mammalian skin onto a live host, permitting the mammalian skin to remain on the host for a predetermined period of time, removing the mammalian skin, and extracting the protein from the skin. Methods of controlling melanogenesis in pigmentary cells or selectively destroying melanoma cells comprise the steps of mixing an effective amount of melanogenic inhibitor protein, or an active segment, derivative, or analog thereof, with a suitable carrier, and applying this mixture to the pigmentary or melanoma cells. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,719,174 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,719,174 Tue, 17 Feb 1998 00:00:00 GMT The use of antioxidants having indenoindole structure as additives to organ preservation solutions. Such a preservation solution is useful both for in site organ treatment in the donor and for organ storage after the organ is harvested. The present invention also discloses an improved organ preservation solution. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,697,421 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,697,421 Tue, 16 Dec 1997 00:00:00 GMT The present invention provides a method for infrared pressureless infiltration of composites, including infiltration of carbon fibers and silicon carbide fibers with aluminum and titanium matrices. Composites produced by the methods of the present invention are also included within the scope of this invention. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,681,617 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,681,617 Tue, 28 Oct 1997 00:00:00 GMT The present invention provides a method for application of metal coatings, specifically copper and silver, to continuous ceramic fibers, by electroless deposition. The method comprises the steps of: winding the uncoated ceramic fibers over a frame so that the fibers are coiled adjacent to each other; introducing the wound ceramic fibers into a solution of metal with which the fibers are to be coated; circulating the solution through said fibers; and contacting and causing the metal to be deposited on the wound fibers. Coated continuous ceramic fibers produced by the method of the present invention are also included within the scope of this invention. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,674,521 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,674,521 Tue, 07 Oct 1997 00:00:00 GMT A method of loading a drug into a crosslinked polymer network and protecting the drug from the effects of inactivation is described. The method includes the steps of contacting a biologically active solute (e.g. drug) with: (i) a gel network; (ii) a loading polymer that is somewhat immiscible with the gel; and (iii) a salt, under conditions sufficient for the biologically active solute to selectively partition into the gel and the salt and the loading polymer to be entrained in the gel. A drug delivery system including a polymer gel network and the drug to be delivered is also described. The system also includes a salt and/or a loading polymer. The system protects the drug from loss of activity. In one embodiment, the polymer gel network is capable of expanding or collapsing in response to a change in an environmental condition to which the gel is exposed, the expanding or collapsing sufficient to release the drug into an environment of use. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,658,588 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,658,588 Tue, 19 Aug 1997 00:00:00 GMT A method for preparing fibrinogen-coated liposomes is disclosed. In this process, fibrinogen and an acylating agent are reacted in the presence of a dispersion of liposomes under specifically defined reaction conditions. The liposomes formed using this process, pharmaceutical compositions containing those liposomes, and the methods of clotting blood and delivering pharmaceutically-active agents and/or other chemicals utilizing those pharmaceutical compositions are also disclosed. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,651,874 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,651,874 Tue, 29 Jul 1997 00:00:00 GMT Carbon-containing components (1, 2, 5) of cells for the production of aluminium (8) by the electrolysis of alumina dissolved in a cryolite-based molten electrolyte (7) are protected from attack by liquid and/or gaseous components of the electrolyte (7) in the form of elements, ions or compounds, by a refractory boride coating (9, 10, 11) applied from a slurry composed of preformed particulate refractory boride in a colloidal carrier which is dried and heated to consolidate the coating. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,629,001 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,629,001 Tue, 13 May 1997 00:00:00 GMT An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and microencapsulated with a water emulsifiable enteric coating composition. The microcapsules are orally administered. The coating protects the protein as it passes through the stomach. Upon reaching the small intestines, the basic pH of the intestinal juices will dissolve the coating, allowing the protein to be released and induce antigen specific immune response which has the specificity of the native molecule. The stabilizing agent protects the therapeutic protein from denaturation during the encapsulation process. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,612,060 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,612,060 Tue, 18 Mar 1997 00:00:00 GMT An improved immunomodulatory therapy for enhancement of depressed host defense mechanisms as shown by improved allograft survival rates is disclosed. The therapy comprises the synergistic combination of an immunomodulatory diet consisting of an amino acid such as arginine, ornithine and their salts, a nucleotide such as RNA and fish oil as a source of omega-3-fatty acids together with an immunosuppressive treatment comprising the administration of a donor specific transfusion and cyclosporine. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,604,203 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,604,203 Tue, 18 Feb 1997 00:00:00 GMT The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,603,955 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,603,955 Tue, 18 Feb 1997 00:00:00 GMT A method of loading a drug into a crosslinked polymer network and protecting the drug from the effects of inactivation is described. The method includes the steps of contacting of a biologically active solute (i.e., drug) with:(i) a gel network; (ii) a second protectant polymer that is somewhat immiscible with the gel; and (iii) a protectant salt, under conditions sufficient for the biologically active solute to selectively partition into the gel and the protectants to be entrained in the gel. Most preferably, the gel network is a crosslinked gel responsive to a change in an environmental condition to which the gel is exposed. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,591,433 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,591,433 Tue, 07 Jan 1997 00:00:00 GMT An orally administrable therapeutic protein is provided by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated onto nonpareils and microencapsulated with a water emulsifiable enteric coating composition. The microcapsules are orally administered. The coating protects the protein as it passes through the stomach. Upon reaching the small intestines, the basic pH of the intestinal juices will dissolve the coating, allowing the protein to be released and induce antigen specific immune response which has the specificity of the native molecule. The stabilizing agent protects the therapeutic protein from denaturation during the encapsulation process. In addition to being immunogenic, when administered orally, encapsulated allergen has a therapeutic effect in the treatment of human allergies. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,585,475 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,585,475 Tue, 17 Dec 1996 00:00:00 GMT Peptides capable of binding calmodulin are disclosed. The peptides surprisingly do not exhibit strict .alpha.-helical conformations. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,573,994 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,573,994 Tue, 12 Nov 1996 00:00:00 GMT An absorbent, microporous foam comprising a crosslinked polymer having interconnected fluid cells distributed throughout its mass, wherein the fluid cells have a diameter of between about 0.1 and about 100 .mu.m, and wherein the foam can rapidly absorb at least about twice its dry weight in fluid, is disclosed. A method for producing a microporous, absorbent foam is also disclosed. This method comprises the steps of: (a) mixing a cross-linkable polymer and a first solvent to form a stable solution, wherein the stable solution can be induced to phase separate; (b) inducing the stable solution to phase separate into a polymer-concentrated phase and a polymer-dilute phase after a predetermined period of time; (c) inducing crosslinking of said polymer, so that the polymer will crosslink in said concentrated phase for a predetermined period of time during phase separation to thereby form a microporous material; and (d) drying the microporous material to produce the absorbent foam. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,535,128 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,535,128 Tue, 09 Jul 1996 00:00:00 GMT A hierarchical control PLD system controls deposition processes by feedback means, for industrial production of tribological thin films. PLD process system identification, intelligent feedback control architecture, and implementation for ultraviolet pulsed laser deposition processes are provided. This system has three levels of feedback control. The first level of feedback control improves the precision and tracking of sub process variables by linear observer based compensator control. The Mo I plume species density per laser pulse and bulk substrate thickness by the quartz crystal micro balance provide real time sub process data to the observer. The observer based compensator then directly calculates laser energy density per pulse and pulse repetition rate based on the current values predicted by the linear model. The second level consists of a dynamical system design algorithm and nonlinear process map. The nonlinear mapping is used to design a new observer based compensator for each linearization point chosen by the third level of control. The third level features an expert system rulebase and command inputs to achieve a desired product goal. The expert controller decides whether or not the process linearized model used by the first level of control is accurate enough to achieve the desired process goals. Based on controller-process performance, a controller re-design is commanded by the third level to the second level, and then implemented by the first level. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,534,119 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,534,119 Tue, 09 Jul 1996 00:00:00 GMT Carbon-containing components of cells for the production of aluminum by the electrolysis of alumina dissolved in a cryolite-based molten electrolyte are protected from erosion by non-chemical attack due to movement of liquid and/or gaseous components of the electrolyte, by a refractory boride coating applied from a slurry composed of pre-formed particulate refractory boride in a colloidal carrier which is dried and heated to consolidate the coating. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,510,008 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,510,008 Tue, 23 Apr 1996 00:00:00 GMT An anode for the electrowinning of aluminium by the electrolysis of alumina dissolved in a molten fluoride electrolyte comprises a porous combustion synthesis product of nickel, aluminium, iron, copper and optional doping elements in the amounts 60-90 wt % nickel, 3-10 wt % aluminium, 5-20 wt % iron, 0-15 wt % copper and 0-5 wt % of one or more of chromium, manganese, titanium, molybdenum, cobalt, zirconium, niobium, yttrium, cerium, oxygen, boron and nitrogen. The combustion synthesis product contains metallic and intermetallic phases. A composite oxide surface is produced in-situ by anodic polarization of the porous combustion synthesis product in a molten fluoride electrolyte containing dissolved alumina. The in-situ formed composite oxide surface comprises an iron-rich relatively dense outer portion, and an aluminate-rich relatively porous inner portion. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,507,933 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,507,933 Tue, 16 Apr 1996 00:00:00 GMT A cell component for use in particular as anodes, cathodes and cell linings of cells for the electrolysis of alumina for the production of aluminum, comprising a solidified carbon containing paste consisting essentially of a compact mixture of one or more particulate carbonaceous material(s) with a non-carbonaceous binder and optionally with one or more fillers to form a fluid paste, the binder being a suspension of one or more colloids or being derived from one or more colloid precursors or colloid reagents optionally with chelating agents. A method of producing the cell component is also included. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,433,976 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,433,976 Tue, 18 Jul 1995 00:00:00 GMT Painted metal sheet pretreated with an insoluble, composite layer containing siloxane. The composite layer is formed by rinsing the sheet with an alkaline solution containing at least 0.005M of a dissolved silicate or a dissolved aluminate, at least 0.1 vol.-% of an organofunctional silane and at least 0.02 vol.-% of a crosslinking-agent having two or more trialkoxysilyl groups. After the sheet is dried, the composite layer has a thickness of at least 10 .ANG.. After being painted, the siloxane forms a tenacious covalent bond between the paint and the metal substrate. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,416,861 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,416,861 Tue, 16 May 1995 00:00:00 GMT An optical waveguide H-tree design is provided for global clock distribution on multichip modules (MCM) which has nearly zero clock skew and is useful for a distributed computer system environment. The optical waveguide H-tree design utilizes channel waveguides, curved sections and directional couplers formed using silica glass and silicon oxynitride (SiON) channel waveguide technologies. A hybrid combination of both SiON and silica glass is disclosed which has the advantages of each. The achievable clock speed is limited by the laser diode source and photodiode receiver at each chip module, and not by the optical waveguide distribution network. The high-speed optical waveguide can be configured to transmit clock signals, or for use as a multi-wavelength communication network that communicates signals to various integrated circuits (ICs) mounted on the multichip module. This is achieved using multiple laser diodes having different output wavelengths and directing their outputs into an optical multiplexer. At the receiving points on the ICs, optical demultiplexers filter the optical signals into individual output signals. In addition, multiple "stacked" optical waveguides can be constructed on the MCM to transmit multiple optical signals, and such optical signals can be either of single wavelength or multiple wavelength type. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,415,126 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,415,126 Tue, 16 May 1995 00:00:00 GMT A method of forming crystalline silicon carbide films is disclosed. The method comprises a chemical vapor deposition process in which a substrate is heated to a temperature above about 600.degree. C. in the presence of a silicon containing cyclobutane gas. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,318,730 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,318,730 Tue, 07 Jun 1994 00:00:00 GMT A method and composition for stabilizing and isolating hazardous, radioactive or mixed waste materials of particulate and solid types, which comprises providing a non-toxic one component aqueous mixture of an acrylic polymer containing a thixotropic agent, a vinyl acetate-ethylene copolymer containing a thixotropic agent, or a vinyl chloride copolymer latex containing a thixotropic agent, and applying the mixture over surfaces of hazardous material in an amount sufficient to form a flexible impermeable coating or foam. The mixture may be applied by spraying to form a coating having a thickness of about 0.5 to about 5.0 centimeters when dry. The coated waste material may then be disposed of in conventional manner. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,240,571 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,240,571 Tue, 31 Aug 1993 00:00:00 GMT The concentration of NADH or NADPH in a test solution is determined by adding a redox coupling agent, preferably 2,6 dichloroindophenol DCIP, to the test solution. The coupling agent reacts with the NADH or NADPH to form an electroactive coupling agent (DCIPH.sub.2) which is then detected electrochemically at a lower voltage than would be required to detect the NADH or NADPH. This can be used to detect NADH or NADPH formed by any well known enzymatic or immunoassay method which produces NADH as a detectable product. This has particular application to biological fluids such as whole blood which does not require any treatment of the test sample prior to electrochemical analysis. In particular, red blood cells do not have to be removed from whole blood samples to provide reliable data. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,231,877 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,231,877 Tue, 03 Aug 1993 00:00:00 GMT A solid state microanemometer is micromachined from a crystal to a shape with four thick external sides that define an outer rectangle, four thin sections that define an inner rectangle and four diagonally directed branches interconnecting the corners of the outer rectangle to the inner rectangle. Four semiconductor resistors located on the four inner sections form a sensing bridge. Each external side has a pair of electrical contacts that are electrically interconnected, via conductive leads that extend along the diagonal branches and partially along the inner sections, to one of the semiconductor resistors. The physically connected semiconductor resistors and external sides form a rugged solid state device, while thermal and electrical isolation of the resistors from each other permits higher operating temperatures and improved fluid flow sensing capability. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,196,670 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,196,670 Tue, 23 Mar 1993 00:00:00 GMT An apparatus is provided for the production of plasma. An evacuable chamber is operatively connected to a microwave waveguide, down which microwave energy at approximately 2.45 GHz is transported. The microwave energy enters the evacuable chamber through an opening in the upper wall of the chamber covered by microwave transparent material. Centrally located above the opening in the upper wall of the chamber and outside the waveguide, a permanent magnet is provided. The strong downward magnetic field of the magnet enters the chamber in the same direction as the propagation path of the microwaves. The downward magnetic field component is at a right angle to the electric field associated with the microwaves. A working gas is introduced to the chamber by a plurality of gas inlets operatively connected to the chamber. At some point within the vacuum of the chamber, the electrons rotating about the downward magnetic field component are in phase with the electric field of the microwaves. These electrons acquire sufficient energy at this point to dissociate molecules of the working gas into atoms and to remove electrons from atoms to form ions and free electrons. This plasma of ions, electrons and atoms is then used to perform work on a workpiece provided on a support with the chamber. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,175,692 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,175,692 Tue, 29 Dec 1992 00:00:00 GMT A method and apparatus are described for automatically palletizing parcels of various sizes, shapes and contents which arrive in random order at a pickup point to be transferred onto a pallet. A system is disclosed including a digital computer operating under an expert computer program which takes information about attribute factors of the parcels and applies predetermined rules to assign a space for the parcel on the pallet, and communicates coordinates of the assigned space to a flexible material handling robot. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,142,027 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,142,027 Tue, 25 Aug 1992 00:00:00 GMT A conjugate of a protein carrier and an antigen is disclosed. The carrier protein is cationized and the conjugate has enhanced immunogenic properties over those of the antigen alone. Cationization can be accomplished by derivatization of native carboxyl groups on the protein with an aklyl diamine, e.g. ethylene diamine, resulting in the formation of side chain aminoalkylamide groups, e.g. aminoethylamide. http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,109,843 http://www.ipo.uc.edu/index.cfm?fuseaction=patents.results&item_number=5,109,843 Tue, 05 May 1992 00:00:00 GMT A method of providing extracorporeal to intracorporeal power transfer in a patient employs a cylindrical primary coil inserted into a segment of small intestine which has been separated and closed at one end. The open end is attached to the abdominal wall providing an opening to the exterior of the body. A secondary coil is formed by wrapping a wire around the serosa of the segmented small intestine. This is in effect a transformer which will transfer energy from the primary coil to the secondary coil. The vascularization of the segment provides for rapid and efficient heat dissipation. This device can be used to power heart assist devices and artificial hearts. Since it is located in an internal pouch, proper location of the primary coil is ensured.